Multimillion dollar investment.
Takeda Research Investment, Inc. (TRI), based in Palo Alto,
California, has made a strategic equity investment of $5 million in
Xenon Pharmaceuticals, Inc. (Vancouver, Canada). The companies have
agreed that TRI will receive a Right of First Negotiation to select
atherosclerosis discoveries made by Xenon.
Please send news releases to:
Alex Cheng
Assistant Editor
PRODUCT MANAGEMENT TODAY
66 Palmer Ave.
Bronxville, NY 10708
Phone: (914) 337-7878, ext. 215
Fax: (914) 337-4987
E-mail: Alex.Cheng@PMToday.com
Please send company logos as well.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Copyright ©
Entrepreneur.com, Inc. All rights reserved.
Privacy Policy